Panagene Inc
Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company a… Read more
Panagene Inc (046210) - Total Assets
Latest total assets as of September 2025: ₩101.91 Billion KRW
Based on the latest financial reports, Panagene Inc (046210) holds total assets worth ₩101.91 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Panagene Inc - Total Assets Trend (2005–2024)
This chart illustrates how Panagene Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Panagene Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Panagene Inc's total assets of ₩101.91 Billion consist of 63.4% current assets and 36.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩35.91 Billion | 32.8% |
| Accounts Receivable | ₩3.81 Billion | 3.5% |
| Inventory | ₩3.98 Billion | 3.6% |
| Property, Plant & Equipment | ₩14.28 Billion | 13.0% |
| Intangible Assets | ₩2.92 Billion | 2.7% |
| Goodwill | ₩6.61 Billion | 6.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Panagene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Panagene Inc's current assets represent 63.4% of total assets in 2024, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 32.8% of total assets in 2024, up from 0.8% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is cash and equivalents at 32.8% of total assets.
Panagene Inc Competitors by Total Assets
Key competitors of Panagene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Biotoxtech Co. Ltd
KQ:086040
|
Korea | ₩132.45 Billion |
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
|
Idogen AB
ST:IDOGEN
|
Sweden | Skr5.12 Million |
Panagene Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Panagene Inc generates 0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Panagene Inc is currently not profitable relative to its asset base.
Panagene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.46 | 18.91 |
| Quick Ratio | 2.04 | 2.33 | 15.70 |
| Cash Ratio | 0.00 | 0.24 | 0.00 |
| Working Capital | ₩27.01 Billion | ₩ 45.69 Billion | ₩ 17.59 Billion |
Panagene Inc - Advanced Valuation Insights
This section examines the relationship between Panagene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.98 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 20.6% |
| Total Assets | ₩109.61 Billion |
| Market Capitalization | $29.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Panagene Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Panagene Inc's assets grew by 20.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Panagene Inc (2005–2024)
The table below shows the annual total assets of Panagene Inc from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩109.61 Billion | +20.57% |
| 2023-12-31 | ₩90.91 Billion | +162.20% |
| 2022-12-31 | ₩34.67 Billion | +8.66% |
| 2021-12-31 | ₩31.91 Billion | +17.18% |
| 2020-12-31 | ₩27.23 Billion | +24.99% |
| 2019-12-31 | ₩21.79 Billion | -9.51% |
| 2018-12-31 | ₩24.08 Billion | -13.69% |
| 2017-12-31 | ₩27.90 Billion | -15.52% |
| 2016-12-31 | ₩33.02 Billion | +28.78% |
| 2015-12-31 | ₩25.64 Billion | +0.53% |
| 2012-12-31 | ₩25.51 Billion | -39.88% |
| 2011-12-31 | ₩42.42 Billion | +10.73% |
| 2010-12-31 | ₩38.31 Billion | +16.47% |
| 2009-12-31 | ₩32.90 Billion | -34.57% |
| 2008-12-31 | ₩50.28 Billion | -0.79% |
| 2007-12-31 | ₩50.68 Billion | -13.62% |
| 2006-12-31 | ₩58.67 Billion | -7.48% |
| 2005-12-31 | ₩63.42 Billion | -- |